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Organophosphorus compounds (OPs) such as tabun, sarin and soman have been 
used as chemical warfare nerve agents.  The advancements of chemical warfare agents 
used for military tactics exceed the research to reverse the toxic effects of the nerve 
agents. The demand to study OP nerve agents is crucial because of the damaging effects 
to people, the commercial availability, terrorist usage, and even the stockpiles in various 
countries. OP pesticides are also of significant concern as the largest number of deaths 
occurs due to exposure to such pesticides, especially in the third world. Exposure to OPs 
affects the central nervous system and causes a buildup of acetylcholine in the body by 
inhibiting acetylcholinesterase (AChE).  The AChE is initially inhibited, followed by an 
aging process. There are known therapeutic oximes for reactivating the inhibited form of 
AChE; however, there are no known treatments for aged AChE. We are developing a 
library of quinone methide precursors (QMPs) to be used as potential re-alkylators in 
order to reverse the aging of AChE. These QMPs can be used to potentially re-alkylate 
the aged OP-AChE complex, followed by a subsequent reactivation step.  This research 
is vital to enhance the pharmaceutical measures and further inspire more research done 
to counteract the aging process. Several frameworks were synthesized through synthetic 
routes including nucleophilic substitution, reductive amination, and Mannich reactions.  
We will present the synthesis of a small library of pyridine QMP frameworks and the 
screening of these compounds as re-alkylators and re-activators of both the inhibited and 
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Chapter 1. Introduction 
 
The development of catastrophic weapons has been a common practice by various 
countries for centuries. For over 2,000 years, civilizations have been developing 
poisonous weapons to defend or conquer disputes.12 More specifically, chemical warfare 
dates back as early as 600 B.C Greece, where the Athenians poisoned the Spartan’s 
water supply of the city of Kirrha with a cardiac toxin derived from the Hellebore plant.6 In 
counter tactics, the Spartans attempted to burn sulfur to create the first toxic smoke which 
was deployed on Athens.12 Similarly, Genghis Khan attempted the same war tactic of 
burning sulfur pitch during the siege of fortified cities in 1200 A.D.12 Over the centuries, 
armies continued to utilize chemicals such as the common war tactic of plant extracts to 
poison arrows in order to optimize their attacks and enemy causalities. Sadly, this was 
just the beginning of chemical warfare tactics that civilizations have used to attain power.  
Advancements in science and chemistry have helped millions of people with the 
development of antibiotics in medicine; however, the scientific development of toxic 
chemicals has also harmed millions of people through advanced chemical warfare. 
Civilizations’ natural tendencies are to attain power; therefore, they will utilize not only the 
bodies or strength of people but also their intelligence to develop weapons and chemicals 
to kill enemies in mass quantities while minimizing their own people’s casualties. Bombs, 
missiles, and guns were not enough for some countries.12 Sadly, countries developed 
methods to evoke emotional responses when killing mass amounts of people.12 This led 
to chemical warfare because the chemicals are often invisible (gas) and people suffer a 
slow and agonizing death. Therefore, country’s use of chemical warfare agents eliminated 
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the physical strength between two groups in war, which can be seen throughout history 
from the Americans in the American Civil War to the Germans in WWI.  
In 1861, during the American Civil War, both armies utilized chemical weapons 
such as spraying chloroform, sulfuric acid, deploying poisonous gases (chlorine gas), and 
even filling grenades with arsenic-containing liquids.6 In 1915 during WWI, the Germans 
dispatched over 170 metric tons of chlorine gas on the Allied troops.17 As a result, more 
than 1,100 soldiers died and 7,000 were injured.9 Throughout WWI, the Allies and the 
Germans used phosgene, diphosgene, mustard gas, hydrogen cyanide and cyanogen 
chloride (Figure 1.1).9 Due to these extreme tactics, the United States opened a facility in 
Maryland to research chemical weapons. In total after WWI, 90,000 to 100,000 people 
died from chemical weapons, primarily due to poisonous gases.17 These two wars were 
just the start of the ‘chemists’ war’. The power strike of countries blinded them to the 
devastation of delving into creating even more powerful chemical weapons without 
thinking about the counterpart of mass destruction. These countries deploy poisonous 
gases without containment or control over the span of area that a gas can cover, thus 
leading to millions of civilians and innocent people dying.  
 
Figure 1.1. Chemical Warfare agents 
 
The other side to this devastation is ‘how do we prevent poisonous gas from killing 
thousands of soldiers and civilians?’ During the chemist war in 1914-1918, the Allies 
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developed full body protection from the poisonous gases.6 This included gas masks 
(Black Veil Respirator, reminiscent of bandit’s mask) and fully-body canvas cloaks with 
transparent plastic viewing windows.6 The filters in the gas mask either deactivated the 
poisonous air through contact with charcoal or trapped larger poisons as gas molecules 
with filters containing acid neutralizing or oxidizing agents.6 Due to these advancements, 
casualties on both sides dwindled and yet again the two sides were at a stalemate until 
one side developed a more powerful chemical that penetrated the clothing and masks.  
             The allies and Germans utilized science, and more specifically advances in 
chemistry as a way to kill a large number of people versus ways to help or cure people. 
The stalemate ended in 1936 during the buildup to WWII, when a German chemist, 
Gerhard Schrader, was trying to synthesize a new pesticide to preserve food, but 
accidently created tabun, the first deadly organophosphorus compound (OPs) or nerve 
agent.6 The Nazis manipulated his research from a pesticide to create three new chemical 
warfare agents: tabun, sarin and soman.7 These three nerve agents are commonly known 
as the G agents: GA (tabun), GB (sarin) and GD (soman), refer to Figure 1.2, which were 
named after Gerhard Schrader.  
 
Figure 1.2. Common OP compound’s structures used for both chemical warfare and 
pesticides 
  During WWII, Schrader furthered his research and developed a series of fluorine 
containing esters such as di-isopropyl fluorophosphate (DFP) and sarin, pyrophosphate 
esters including TEPP and octamethylpyrophosphortetramide (OMPA), and thio- and 
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thionophosphorus esters including parathion and its oxygen analog paraxon.16 The 
pharmacological and toxicological studies of the Schrader’s compounds were tested and 
the results showed that the toxicity and potency of the chemicals prevented them to be 
used for insecticides. However, these compounds were considered as potential chemical 
warfare agents. The Germans stockpiled tons of nerve agents which were never deployed 
on the Allies, but some poisonous gases were used in concentration camps. The stock 
piles include a total of 12,000 tons of tabun and more than 50,000 tons organic 
phosphorous compounds have been developed.16 After WWII, researchers from both 
sides shared their knowledge and mechanistic effects of the nerve agents. This led to a 
new series of more stable nerve agents known as the V agents – refer to Figure 1.3. V 
agents are sulfur-containing agents and are approximately ten-fold more toxic than 
sarin.10 Members of the V series were initially synthesized by the British government.16 In 
addition, the United States mass produced 4400 tons of VX from 1961 to 1968.16  
 
Figure 1.3. V series and pesticides  
Some of these OPs have been used in recent times; during the Iran and Iraq war, 
different OP nerve agents were dispatched by the Iraqis against the Iranians. The Iraqi 
forces proceeded to attack the Kurdish city of Halabjah, deploying both sarin and tabun.1 
Due to the lack of containment or controlled deployment to a specific enemy area, the 
attack killed 5,000-8,000 people including soldiers and civilians.16  
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Aside from using chemical warfare agents as war tactics, if these nerve agents 
were to get in the wrong hands, it could lead to chemical terrorism. The first reported 
chemical terrorism was in 1994 by the Au, Shinrikyo Cult.16 This cult deployed sarin gas 
in public places. Shortly after, in 1995, nerve gas, more specifically sarin gas, was 
deployed in a Tokyo subway station by terrorists, killing 13 people and several thousand 
people were injured.16 In 2013, hundreds of Syrian civilians were killed by sarin gas from 
their own government.11  
The usage of Organophosphorus compounds is not limited to chemical warfare 
and terrorism alone but also commonly used as pesticides and herbicides. Less lethal 
OPs are used for pest and disease control for farmer’s crops. These OPs include 
malaoxon, paraoxon and chlorpyrifos oxon currently used in agriculture.16 Even though, 
there has been some improvements of these OP pesticides toxicity, small residues of OP 
toxin can remain in the vegetation and individuals can ingest these toxic crops as well as 
direct OP exposure to agricultural workers. In developing countries, agricultural workers 
reported annual incidences of acute pesticide poisoning were (sadly) 18.2 per 100,000 
full time workers.16 Today, it is estimated that 3 million people are exposed to OP pesticide 
compounds worldwide, resulting in, on average, 300,000 deaths annually.16  
Unfortunately, the antidotes or countermeasures for both OP pesticides and 
chemical warfare have not had such an illustrious history and are rather lacking. The 
advancements of chemical warfare agents used for military tactics exceed the research 
to inhibit the effects of the nerve agents.   
             The demand to study OP nerve agents is crucial because of the damaging effects 
to people, the ease of commercial availability and even the stockpiles in countries waiting 
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to be deployed in case of a terrorist attack. Even more alarming, sarin gas is so highly 
toxic that a single drop of sarin the size of a pin or 800 micrograms is enough to kill a 
single human and most times victims will die in a few seconds.13  
Such OP nerve agents are toxic phosphoryl groups that covalently inhibit the 
enzyme, acetylcholinesterase (AChE). Acetylcholinesterase is an enzyme found in the 
central nervous system and peripheral nervous system that regulates the concentration 
of acetylcholine (ACh) found in the neuromuscular junction by hydrolyzing the ACh 
neurotransmitter. ACh is essential in both the central nervous system and peripheral 
system. In the peripheral nervous system, the major role of ACh is to transmit a signal 
between motor nerve and skeletal muscle to trigger contractions and to move the human 
body.8 Its critical role in the CNS is as a modulator that activates different areas of the 
brain that control attention, memory, arousal and motivation. Due to its essential role in 
the human body, it is essential that the amount of ACh present be strictly governed by 
enzymes. More specifically, AChE regulates acetylcholine by hydrolyzing 5000/25000 
acetylcholine per second into choline and acetic acid by the catalytic triad of the active 
site and the oxyanion hole.15 
 
Figure 1.4. Acetylcholine hydrolysis 
 
The catalytic triad is composed of three key amino acid residues Ser-203, His-447 
and Glu-334, and similar to serine proteases found throughout the body.4 The catalytic 
process starts by the activated Ser-203 nucleophilic attacking the carbonyl carbon of the 
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ACh (Scheme 1.1).4 However, after exposure to the OP compound that is a substrate 
analogue to ACh, the phosphoryl center covalently bonds to the serine residue of the 
active site, which inhibits the enzyme and leads to the accumulation of ACh in the 
neurosynaptic junction (Scheme 1.2).20 An overabundance of ACh can lead to adverse 
effects such as continuous stimulation of muscles, glands and stimulation of the CNS. 
Less severe symptoms include muscle weakness, disorientation and reduced vision.14 
More severe poisoning symptoms include respiratory failure, convulsions, paralysis, 
vomiting, and even death.14 The severity of these OP gases is devastating – only 5 tons 
of sarin at the right concentration would be enough to completely aboliterate all of 
humanity. 
 
Scheme 1.1. The hydrolysis of acetylcholine into choline  
 
The flip side to this devastation is how do we reverse the effects of the OP agents 
or prevent the ingestion of the poisonous compounds. The first attempts started with gas 
masks and full body cloaks or ghost costumes; however, such countermeasures only 
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worked against tear gas, chlorine and phosgene/diphosgene. Mustard gas and the nerve 
agents created after WWI could penetrate the soldiers’ protection gear. Therefore, 
another countermeasure must be taken to prevent these devastating fatalities moving 
forward. In 1951, pharmacological treatment studies hoped to reverse the effects of OP 
compounds.2 There are three pharmacologic treatments that are commonly administered: 
anticholinergic drug (atropine), anticonvulsant drugs (benzodiazepines), and pyridinium 
oximes (Figure 1.5).  
 
Figure 1.5. Current accepted treatments to reverse OP exposure before enzyme is aged. 
 
The first pharmacological treatment was atropine for their parasympathomimetic 
effects.2 The anticonvulsant, benzodiazepine, limits the amount of ACh released in the 
synaptic cleft; therefore, the patient will be less susceptible to convulsions. With the 
combination of benzodiazepine with atropine or pyridinium oximes,19 benzodiazepine with 
atropine will combat both the physical symptoms (convulsions and muscle fasciculations) 
and the chemical problem by reactivating the AChE enzymes.2 Pyridinium oximes, such 
as 2-PAM (Figure 1.5), reactivate the OP-inhibited AChE by nucleophilic attack, thereby 
releasing the phosphonate as a leaving group (Scheme 1.2). This regenerates the native 




Scheme 1.2. Organophosphorus inhibition of AChE 
 
However, there are various problems with the use of current pyridinium oximes, 
such as 2-PAM, and atropine. First, the dosage of the amount of oxime administered to 
the patient is dependent on the specific OP inhibiting the active site. The amount and the 
structure of the oxime mediates its effectiveness for a specific OP, and fatal 
consequences can occur if applied incorrectly. Moroever, and leading to the second major 
problem, there is a second step in the OP interaction with AChE.  The inactive and 
inhibited phosphylated serine can be irreversibly dealkylated into the “aged” OP-AChE 
complex (Scheme 1.3). This aged complex can not be reactivated by pyridinium oximes. 
Nearby amino acids provide an oxyanion hole that stabilizes the phosphylated anionic 
form of the OP-AChE complex, making it more favorable in this irreversible form.7 The 
time period for aging to occur depends on the OP inhibiting the enzyme and Table 1.1 
provides some half times to aging for different OP compounds.20 Lastly, all of the currently 
accepted treatments for reactivators are positively charged, such as pyridinium oximes; 
consequently, the drug can not pass the blood brain barrier to reactivate the AChE in the 
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CNS. This will cause a buildup of ACh in the brain leading to fatal effects. Currently, there 
is a deficit of pharmaceutical measures to medically counteract the aging process from 
OP exposure.  
Organophosphorus Compound Aging time 
Soman 2 minutes 
Sarin 5 hours 
Cyclosarin 22 hours 
VX/tabun >40 hours 
Table 1.1. Rates of aging for different OP compounds20 
 
Scheme 1.3: Process of reversible inhibition and irreversible aging of AChE by sarin. 
 
In the different research efforts for countermeasures against OP poisoning, there 
have been four focused research efforts to treat OP-aged AChE. First, one effort includes 
slowing down the aging process. The key mechanism of this solution is to have a drug 
that slows down the aging process; thereby, allowing more time for other drugs to 
reactivate the inhibited AChE before it becomes aged. In 1996, Berry and Davies were 
the first to successfully prove the capability of effectors to slow down the aging process. 
They reported 2-40 mM N-methylpyridinium iodide lowered the aging rate of soman-
inhibited AChE by 33-69% and cyclosarin-inhibited AChE by 52-100%.19 In 1970, Crone 
reported results for how six quaternary ammonium compounds affect the aging kinetics 
of sarin, and from that work, one effector slowed down the aging rate by 77%.19 In 
addition, van Dongen et al. tested atropine, a common treatment for OP poisoning, 
slowed down the aging of sarin-inhibited rat and human AChE by 28-60%, but at a dose 
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of 1 mM.19 This dosage of atropine is orders of magnitude higher than the clinical dosage 
of atropine, so these effects are never seen, thus leading to the key reason that this 
method of treatment is not currently used. The effectors must be administered at a high 
mM concentration, which is too high for clinical treatment and creating other toxic issues 
for humans. In addition, the main purpose of the effectors is to slowdown the aging 
process; therefore, the root problem of OP inhibition is still there. Once all of the AChE 
becomes aged, the effectors will have no impact and the problem to resurrect or realkylate 
the AChE is still in play.  
The second and third method includes up-regulating the expression of AChE and 
introducing exogenous AChE. These methods both showed the newly synthesized AChE 
and exogenous AChE can replace any impaired AChE (inhibited or aged), therefore, 
recovering the AChE activity in the victim.19 However, both strategies cannot resurrect 
aged AChE; thus, the problem of resurrecting the aged AChE is still relevant.  
Lastly, the attempt to realkylate the aged AChE has offered the most promising 
solution to undo the aging process. Although many organic molecules can be 
synthesized, it is critical for one specific molecule to have the correct reactivity and 
orientation to re-alkylate the aged AChE. More specifically, the goal is to reverse the 
dealkylation of the oxyanion of the phosphyl group; therefore, the negatively charged 
phosphyl group will be neutralized after re-alkylation. This solution paired with reactivation 
drugs such as 2-PAM will return the AChE to its native form. Across the decades, various 
types of organic molecules as electrophilic molecules have been tested to re-alkylate 
aged AChE.  
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Sulfonate molecules were the first molecules to be tested to re-alklate aged AChE 
because they are good leaving groups. In 1969, Blumbergs et al. synthesized a library of 
sulfonic esters.19  The year after, α-haloketones were evaluated for a solution because of 
the increased electrophilicity of the α-carbon.19  Steinberg et al. made a library of 
haloketones consisting of 20 alkylating agents.19 More specifically a bromoketone was 
experimentally proven to realkylate a model compound as a methylphosphonate; 
however, Steinberg was unsuccessful in demonstrating any realkylation of in vitro aged 
AChE.19 In 2013, a series of methoxypyridinium derivatives were evaluated for their ability 
to re-alkylate aged AChE by transferring methyl groups to the nucleophilic oxygen.19 Two 
reaction mechanisms were proposed, as shown in Figure 1.6. However, there have not 
been any reports of the success of these molecules for their alkylation ability in an in vitro 
experiment with aged AChE. 
 
Figure 1.6. Quinn et al. proposed two possible mechanisms of methyl transfers for 
realkylation19  
 
Similarly, sulfoniums were evaluated for their capabilities in biological 
transmethylation also known as (S)-adenosyl methionine.19 This study made a 
breakthrough in demonstrating the orientation that the drug enters the active site is 
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critical. In this study, the researchers used a force field to ‘pull’ the compound out of the 
active site and, and the orientation of the compound flips as it enters or leaves the active 
site. This gives the compound the ability to react with the active site in all orientations 
instead of the its original docking in the active site. Their mechanistic capabilities are 
shown in Figure 1.5. These molecules were never tested for their alkylation ability.  
 
 
Figure 1.7. Chandar et al purposed methyl transfer reaction with sulfonium compound19 
 
A promising family of organic electrophiles are quinone methides (QM) and 
quinone methide precursors (QMP).  In 2004, Zhou et al. showed that quinone methides 
(QM) have the ability to alkylate different amino acids in vitro.18 These quinone methide 
precursors mimic edrophonium, an oxyanilinium-based inhibitor of AChE that binds to the 
active site.5 The QM were synthesized from quinone methide precursors (QMP) via 
thermal or photochemical means. Many modification and attachments on the aromatic 
ring have different reactivity properties.5 One initial family of compounds included the 
para-substituted QMPs. In addition, Bakke et al. showed the QMs alkylating properties; 
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however, the QMs were produced from the oxidation reaction with lead oxide and silver 
oxide from QMPs versus the thermal means (Figure 1.8).3  
 
Figure 1.8. General quinone methide structures and the structure of edrophonium. 
The synthesized QMs were found to have re-alkylated a phosphodiester bond and 
lactonized to form a trialkyl phosphate under aqueous conditions.3 Although QMs have 
been shown applied as electrophiles in different applications, none of them have been 
studied as re-alkylators for aged AChE.   
 
Figure 1.9. QM alkylates a phosphodiester bond via lactonization3 
 
However, both studies with QMPs gave way for inspiration and were vital starting 
point for our library of potential resurrectors of aged AChE activity. Using computational 
chemistry, the possible options of QMPs were narrowed down because these methods 
were able to determine the optimal QMPs that had potential reactivity and potential 
orientational preference in the enzyme’s active site.  
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While our lab continues to investigate the mechanism, we have found compounds 
that resurrect aged AChE. We hypothesized that these compounds re-alkylate aged 
AChE followed by a reactivation step to produce active uninhibited AChE. One of the 
most successful resurrectors in our lab is shown in Figure 1.10. The objective of my 
research is to explore two key questions and to aid in our understanding of their mode of 
action. The questions include: ‘how different amines substitution will affect resurrection’, 
‘how blocking the phenolic oxygen will affect resurrection’, and ‘how adding a substituent 
on the benzylic carbon will affect resurrection’. This report will unfold the process of 
answering these questions by first synthesizing, purifying, and screening the organic 
molecules for resurrection.  
 
Figure 1.10. One of our most successful resurrectors: 2-(pyrrolidine-1-ylmethly)pyridine-
3-ol. 
 
 In summary, organophosphorus compounds inhibit human AChE, which may 
cause fatal effects on humans. Current treatments, such as 2-PAM, have proven to 
reverse the inhibition processes; however, limitations with these drugs include its ability 
to pass the blood brain barrier, optimal dosage, and correct time frame of dosage 
administration. The major concern is the time frame of administration because if an oxime 
is not given at the right time, the AChE becomes aged or the “OP-AChE” complex 
dealkylates (Figure 1.11). Current standards of care cannot resurrect this irreversible 
aging process. Resurrection is the process of a compound’s ability to re-alkylate the aged 
enzyme, followed by reactivation to produce active AChE. Therefore, this research aims 
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to synthesize quinone methide precursors to be used as potential re-alkylators of aged 
AChE, followed by reactivation with current treatments (2-PAM) or a different reactivator. 
In addition, this research is vital to enhance the pharmaceutical measures and further 
inspire more research to be done to medically counteract OP exposure.    
 
Figure 1.11. Research Significance 
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Chapter 2. Synthesis of Organic Molecules 
 
Introduction 
 The rapid rate of new and evolving diseases and illnesses is becoming a serious 
problem due to the treatments and drugs not being able to keep up with these devastating 
elements. However, synthetic chemistry or drug development has helped to hinder the 
spread of disease.4 Organic synthesis paved the way to produce important compounds 
that save and improve millions of people’s lives by providing small drug-like materials that 
can eradicate illnesses and diseases.4  
 The start of total synthesis began in 1828 of urea by Wohler (Figure 2.1).4 This 
major breakthrough not only was the first documented total synthesis but was the first 
time an organic molecule was made into an inorganic molecule. This major stepping stone 
in total synthesis paved the way for the tools to design natural products, conformational 
information and structure, and discovery of new biologically important molecules.  
 
Figure 2.1. Synthesis of Urea 
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 This led to the realization that natural products can be constructed and 
manipulated to enhance and optimize its curing properties of diseases and illnesses 
through total synthesis. Total synthesis is a complex and arduous process to complete 
for complex molecules.4 For these procedures, the atoms must be constructed in a 
specific orientation and position throughout the reaction scheme. In addition, the order of 
the reaction steps to which each piece of a molecule can be assembled and constructed 
without affecting a different part of the same molecule.4,15 Therefore, not only closely 
monitoring the steps of the reactions are important, but also the types of reagents, 
temperature and environment conditions.  These are all factors that must be regulated to 
construct the correct molecule and to optimize the final yield of a target compound through 
total synthesis.4  
 Initially, the synthesis of molecules had little innovation or analysis required to 
synthesize the target compounds because the desired compound closely resembled the 
starting materials. As breakthroughs in chemistry, biochemistry, biology, and drug 
synthesis unfolded, it gave rise for a new era of retrosynthetic analysis.16 This entails 
synthesizing more complicated molecules from simple readily available starting material. 
This era began in post-World War II due to the breakthrough of five key advancements in 
synthesis:4 
1. Construction of detailed mechanisms for a host of organic reactions 
2. Introductions of conformation analysis and stereo-chemical studies 
3. New spectroscopic tools for structural analysis 
4. Use of chromatography for analysis and separation 
5. Discovery of new selective chemical reagents 
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This new era of total synthesis was driven by a chemist, R. B. Woodward, who 
contributed to designing natural products such as strychnine, reserpine, and Vitamin B12 
(Figure 2.2).4 More specifically, the novel syntheses were noted by utilizing rings to control 
stereochemical centers. Woodward’s synthesis pathways for his three key target 
compounds starting the building blocks of these complicated synthetic routes.4 The 
synthesis of strychnine was the first alkaloid to be isolated. It was said that Woodward’s 
synthesis “[it] ushered in a golden era of total synthesis and installed unprecedented 
confidence in, and respect for, the science of organic synthesis.”17 Woodward’s second 
major contribution was his synthesis of reserpine through his ability to control 
stereochemistry by using unique ring properties to create it. In 1952, it was proven to 
have vital medicinal properties that include treating hypertension, nervous and mental 
disorders.4 Lastly, his total synthesis of Vitamin B12 contributed to organic chemistry by 
the development of a new synthetic reaction to from a carbon-carbon bond.4 Woodward’s 
contribution was just the start to retrosynthetic synthesis, but it has been the gateway to 
forever change the chemist’s approach to total synthesis and to allow for complicated 
construction of target molecules from simple starting materials to enhance the drug’s 
potency in the body.  
 




After realizing chemists have the capabilities to produce natural compounds, they 
used the techniques to synthetically make organic compounds. The new era of synthetic 
drugs or compounds chemically developed not naturally found in nature began in the 
1900s and continue today.16 This novel technique has not only helped recreate scarce 
natural compounds in mass quantities but also optimizing the activity of the known drugs 
and enhancing and developing new derivatives of drugs as bacteria and virus become 
resistant to the previous drugs.12  
For example, chemical synthesis played a major role in eradicating malaria in tropical 
regions. The cinchona tree bark contained the natural cure to this disease.12 More 
specifically, scientists isolated quinine from the bark, which had the healing properties.12 
Sadly, the cinchona trees began to become extinct; therefore by 1932, only 13% of the 
world’s demand could be supplied.12 Through organic synthesis, German scientists 
constructed quinine substitutes that had the same antimalarial properties.12 The total 
synthetic synthesis played a huge role in developing new antimalarial drugs in large 
quantities from easily available chemicals. Taxol is an anticancer drug that was naturally 
derived from yew root synthetic methods were developed to allow for its production.12 
This paved a new era of readily producing large quantities of natural compounds or 
derivatives of natural compounds through synthetic approach to save thousands of lives 





Figure 2.3. Malaria treatment with quinine  
 
In addition, synthetic chemistry provided a solution to bacteria becoming drug resistant 
to natural antibiotics by developing analogs to the natural antibiotics.9 The major 
contribution to synthetic antimicrobial drugs was Gerhard Domagk.9 He discovered the 
antibacterial activity of synthetic dye, prontosil – more specifically the sulfanilamide 
(active breakdown product of prontosil) that could treat streptococcal infections.9 His own 
daughter was the first human to take the drug.9 The drug completely cured her.9 This was 
the first synthetic antimicrobial created and served as a stepping stone for the discovery 
and production of additional classes of not only synthetic antimicrobials but also other 
classes of drugs. Synthetic chemistry offers hope to diseases that do not have therapeutic 
cure by the ability to manipulate and construct any type of molecule. 
 






Due to the breakthrough in biology providing detailed information at the molecular 
level, drugs have been able to be enhanced through refining the structure, developing 
new structure, or optimizing the known drug activity.16 For example, analogues of an 
original drug such as changing a functional group from methyl, ethyl, or isopropyl have 
enhanced the drug’s purpose.16 Therefore, synthetic chemistry entails not only total 
synthesis or constructing a molecule but also partial modifications to the molecules.  
The ability to modify the functional groups and the structure of drug molecules gives 
us the capability to harness the desired pharmacodynamic and pharmacokinetic effects.8 
The functional groups on a drug molecule are critical for either enhance the drugs activity 
or hinder it. For example the addition or absences of a methyl group or other alkyl chain 
on a drug structure can effect drug’s selectiveness in the active site, its durations and its 
route of administration.8 The alterations could also enhance the activity of the drug, 
increase absorption, decrease adverse effects, or provide other therapeutic benefits.8 
Changing the functional groups affects the overall effectiveness of a drug due to three 
main characteristics of functional groups: electronic effects, solubility and steric effects.1 
For electronic effects, functional groups can either be electronic donating groups or 
electronic withdrawing.1 If the group is electron donating, the it can increase the 
nucleophilicity of a group.   These molecules either contain negative charge or a lone pair 
of electrons that can used to form covalent bonds. In contrast, electron withdrawing 
groups, through induction, pull electron density away from nearby atoms.1 Electron 
withdrawing groups can serve as electrophilic groups or ‘electron loving’. The 
manipulation of the drug’s functional groups can have a critical impact on its effectiveness 
in the body and the target enzyme’s active site.  
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In addition, functional groups dictate the drugs ability to be water or lipid soluble based 
on the polarity, acidic and basic of the functional groups.1 More specifically, the functional 
groups ability to form hydrogen bonds increases its water solubility and hydrophobic or 
nonpolar functional groups tend to be lipid soluble. Lastly, steric effects can have a huge 
impact on the ability of the drug to fit in relevant binding sites. The size of the functional 
groups has a direct impact on the drug’s selectivity, binding interaction, and rate of 
metabolism or degradation.1 In total, the ability to change the structure of a drug through 
addition or absences of functional groups has been proven to effect both its 
pharmacodynamic and pharmacokinetic effects. 
Through the knowledge of both total synthesis and partial modifications of drugs, it 
has been harnessed to develop better drugs for illnesses and diseases. Both of these 
techniques were pivotal in our research of finding antidotes against chemical warfare 
tactics such as nerve agents and even pesticides. Total synthesis and simple 
modifications of synthetic molecules have paved the way for developing and synthesizing 
pharmacological drugs against nerve agents. The chemist researching an antidote to 
nerve agents and pesticides used total synthesis or constructed molecules never made 
before starting with a simple commercially available starting material.12,16 The first 
synthesized organic molecules were to un-inhibit the phosphorylated serine in the 
acetylcholinesterase’s active site. Through retrosynthesis, pyridinium oximes such as 2-
PAM was synthesized and successfully reactivate the AChE (Figure 2.5). However, if left 
untreated after OP inhibition, the OP-inhibited AChE adduct undergoes aging or 
dealkylation. Currently, there are no known therapeutics to reactivate the aged AChE. 
The goal of this thesis is to show how the use of synthetic organic chemistry can be used 
26 
 
to construct novel organic molecules and subsequently test them for their ability to 
reactivate aged AChE. 
Figure 2.5. Current accepted treatments to reverse OP exposure before enzyme is aged. 
 
The key starting point for our frameworks were derived from the research done by 
Bakke and Modica’s synthesis of quinone methides (QMs).19 QMs have been used in a 
biological role of as an alkylator in vivo.19 More specifically, the QMs have alkylated 
phosphodiester bonds at physiological conditions and proven to reversibly alkylate DNA 
and block transcription.19 The modification of the ring and the variability of the amine 
leaving group can highly dictate the reactive ability of the molecule (Figure 2.6). In 
addition, the structure of the quinone methide precursors mimic edrophonium, an 
oxyanilinium-based inhibitor of AChE that is known to bind to native AChE active site.19 
The QM also has the ability to be delivered in an unreactive prodrug form until it is in the 
AChE active site, where it becomes reactive.19 Using synthetic synthesis, QMs are 
derived from benzyl and naphthyl derivatives via silyl cleavage through either oxidative or 
photochemical means.19 
 
Figure 2.6. General quinone methide structures 
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Based on the corresponding structures of QMPs and their known characteristics for 
alkylation and potential affinity for the native AChE active site, our efforts were focused 
on developing candidates to realkylate aged AChE. More specifically, the para-QMPs 
were synthesized first due to their known affinity for the active site as suggested by 
computational modeling.19 In addition to the para-QMPs, more modifications were made 
on the substituents on the ring and the amine leaving group. The library extended to these 
major five aromatic frameworks (Figure 2.7).  
 
Figure 2.7. Family B: potential aromatic frameworks for quinone methide precursors  
 
Based on family B’s success to not only realkylate but also reactivate AChE, we 
decided to explore other frameworks. After testing this framework, it became the lead 
compound in resurrecting the aged form of AChE. This lead to my research that probed 
three major questions. First, how does the amine affect its reactivation capabilities. 
Secondly, what role does the phenolic group play in the reactivation process. Lastly, how 
does substitution at the benzylic carbon affect the reactivation capabilities.  
 





              The methodology of producing re-alkylators and re-activators will be performed 
with synthesis followed by purification techniques. Synthetic methodology includes setting 
up a series of chemical reactions in order to make the objective compound. Some type of 
reactions may include acid/base reactions, nucleophilic substitution, electrophilic 
substitution, and aromatic chemistry. Through combining these reactions in different 
orders, the crude products will be produced and then purified.       
The goal of purification is to isolate the compound from impurities or by-products 
produced within the reaction. Some purification techniques that will be performed are 
crystallization, distillation, gas chromatography, extraction, column chromatography, 
trituration and filtration. These purifications exploit the differences in the specific 
characteristics of the organic compounds such as solubility, polarity, and size of the 
particles.   Simple crystallization utilizes the solubilities as a function of temperature. The 
goal is to have the target compound dissolve in boiling solvent at high temperatures, then 
as the solution cools down crystals form with only the key compound leaving the impurities 
in solution.6 Trituration also takes advantage of the compound’s different solubilities. The 
solvent chosen will dissolve the undesired by-products, leaving the desired product left 
over.14 After the recrystallization or trituration, filtration is performed to filter out the impure 
solution while washing and drying remaining synthetic compound.7 Distillation is a 
purification method that separates compounds based on having different boiling points.18 
The more volatile compound will separate and is then cooled to re-liquefy and collect in 
a container on the other end of the distillation pot or tube. Extraction includes the 
compounds abilities to dissolve in water or organic solvent by using acid-base reactions.13 
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Compounds can easily be transferred to the ionic form by using an acid or base to either 
add or eliminate a proton from one of the compounds. The ionic compound will dissolve 
in the water layer, while the organic compound will remain in the organic solvent, 
separating out the impurities from the target compound.13  Column chromatography is a 
purification method that separates compounds based on their respective polarities.5  The 
mobile phase is the substance that moves the solution being purified and stationary-
phase interacts with the mobile phase which has different characteristics to hinder certain 
compounds to elute first.5  
 Characterization is determining whether the isolated product is the true synthetic 
compound that was intended to be made. Specific techniques used will be melting point, 
boiling point as well as a number of spectroscopic approaches, including nuclear 
magnetic resonance (1H, 13C and 2D NMR), high resolution mass spectrometry, and 
infrared spectroscopy. Melting point and boiling point are physical properties that can are 
used to aid in the identification of the unknown. For melting point, the synthetic compound 
is believed to be pure if the compound melts in a narrow range of 2 ℃ (narrow range: 
initial drop appears then when the entire sample dissolves).2 For boiling point, a pure 
liquid will distill at constant temperature when pressure above gas the gas is equal to the 
vapor pressure.2 The temperatures attained by both, the melting point and boiling point, 
will be compared to the reported literature range for the pure target compound.2 1H-NMR 
and 13C-NMR methods exploit the behavior of the hydrogens and carbons to determine 
the carbon-hydrogen framework of the structure of the target organic compounds.20 
Electromagnetic radiation is used to excite or flip the alignment of the nuclear spin to the 
higher energy opposed state versus the relaxed state spin at lower energy.20 The larger 
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the energy difference between these states, then the greater the magnetic field needed 
to be applied.20 The position of the peaks on the NMR spectrum depends on the relative 
electron richness of the H-type or C-type. For 13C-NMR the radio wave pulses coded with 
angular information determine the number of H’s attached to a carbon signal.20 The 
chemical shift of the signal produced is based on the chemical groups attached to the 
carbon-hydrogen bonds. The more electron dense environments, the lower the frequency 
and the smaller magnetic field applied, the peak is up field. The electron poor 
environments, the higher the frequency or energy, the larger the magnetic field applied to 
flip the nuclear spin, the peak is downfield. This equates to the electronegativity of the 
elements attached. The more electronegative or the more the atom wants to pull the 
electrons toward itself, then the less electron density shielding the proton or carbon, the 
greater the peak to the left.2 Based on these shifts, the chemical compound backbone 
and structure can be assembled to determine the synthetic compounds purity.2 Mass 
spectrometry is used to separate components of a sample by their mass. The sample is 
ionized and passed through a magnetic field, where a detector can plot the spectrum of 
different masses using the mass-to-charge ratio. Using this ratio, the molecular formula 
can be calculated for the compound.2 Infrared spectroscopy measures the vibration of 








Construction of the pyridinium molecules: to the effects of steric or Size of the 
Amine  
2.2. 2-Bromomethyl-3-hydroxypyridine hydrobromide framework- SN2. 
 Pyridine QMPs were synthesized from commercially available 2-bromomethyl-3-
hydroxypyridine hydrobromide (2.2) in a one-step reaction (bimolecular substitution). 
 
Scheme 2.2. SN2 reaction conditions for 2-bromomethyl-3-hydroxypyridine hydrobromide 
frameworks 
 
 The experimental steps were the same for each of the reactions except with the 
change of the secondary amine and temperature of the reactions. This synthesis was 
used to investigate the space that the amine occupies along with the basicity of the 
nitrogen. Compound 2.4 has decreased basicity of the nitrogen atom due to it being in an 
aromatic ring, while Compound 2.3 looks to probe the space and polarity of the hydroxyl 
methyl group.  
 




  The general experimental procedure for the preparation of these compounds 
follows with more specific details at the end of the chapter. The reagents of the reaction, 
2-bromomethyl-3-hydroxypyridine hydrobromide, amine ((S)-2-pyrrolidinemethanol or 
pyrrole), base (sodium carbonate or sodium hydroxide), and acetonitrile were combined 
in a round bottom flask and refluxed. The reaction was monitored and removed form 
heating when the starting material had been consumed. The reaction was monitored by 
thin layer chromatography. The compound was extracted with organic solution (DCM or 
diethyl ether), followed by drying and then the solvent was evaporated under reduced 
pressure. For purification, the compound was analyzed by column chromatography, and 
then dried and characterized by 1HNMR, 13C NMR, HPLC and mass spectrometry 
(Appendix A). 
The next molecule investigated was methoxy pyridine QMPs. These pyridine QMPs 
were synthesized from commercially available 3-methoxypicolinaldehyde in a two-step 
reaction, entailing a reductive amination. The stepwise procedure involved the imine 
formation followed by the reduction with sodium borohydride, resulting in the QMP.   
 
Scheme 2.3. Reductive Amination reaction conditions for 3-methoxypicolinaldehyde 
frameworks 
 
This experimental reaction investigates the importance of the phenolic group of the 
original target compound. The methyl ether group attached to the aromatic pyridine can 




Figure 2.10. Target compound with yield 
 
In order to prepare this compound, we started with 2.3 and performed a reductive 
amination. 3-Methoxypicolinaldehyde was added to an amine, hydrochloric acid, and 
methanol and stirred at room temperature. The reaction’s progress was monitored by TLC 
until the aldehyde was consumed, followed by addition of the reducing agent (sodium 
borohydride). The compound was extracted with DCM. After the extraction, the solvent 
was evaporated under reduced pressure. For purification, the compound was analyzed 
by column chromatography with ethyl acetate and hexanes to yield the target compound. 
The compound was dried and characterized by 1HNMR, 13C NMR, HPLC and mass 
spectrometry (Appendix A). 
We also decided to investigate substitution at the benzylic carbon with a methyl 
group. These compounds were synthesized from the ketone (2.7). Pyridine QMPs were 
synthesized from commercially available 1-(3-hydroxypyridin-2-yl)ethan-1-one (2.7) in a 
two-step reaction, entailing a reductive amination.  
 






The experimental steps were the same for each of the reactions except with the 
change of the secondary amine. The addition of the methyl group at the benzylic carbon 
will provide a better understanding of the mechanism of resurrection with these 
compounds. The six compounds that were synthesized are shown below.  
 
Figure 2.11. Target compounds with yields 
 
The synthesis produced two types of stereoisomers. Compound 2.8 and 2.9 
produced a mixture of two diastereomers because a chiral amine was used. For example, 
the two products produced when (R)-2-methyl pyrrolidine was used are the R,R and R,S 
diastereomers as shown in Figure 2.12. 
 




We made both diastereomers but at this time, we do not know the assignment of 
the configuration at the benzylic carbon after the diastereomers were separated.  
The general procedure to produce these compounds is as follows. The amine ((S)-
2-methylpyrrolidine, (R)-2-methylpyrrolidine, pyrrolidine, or diethylamine) was stirred with 
methanol, while concentrated hydrochloric acid was added dropwise. 1-(3-
Hydroxypyridin-2-yl)ethan-1-one was added and stirred at 73 oC for 12 h to form the imine. 
The reducing agent was added and refluxed for an additional 12 h at 73 oC. The solvent 
was evaporated under reduced pressure.  
When a chiral amine is used, two diastereomers are made in unequal amounts. 
When an achiral amine is used, two enantiomers are produced in equal amounts making 
a racemic mixture. Enantiomers are chiral molecules that are non-superimposable mirror 
images. Each diastereomer has multiple stereocenters and these compounds are not 
mirror images and are not superimposable. Enantiomers have identical physical 
properties except their ability to rotate plane polarized light.10 Due to enantiomers identical 
physical properties, in an achiral environment they cannot be separated. Diastereomers 
have different physical properties and they can be separated.10 More specifically, 
 “one enantiomer may be responsible for the therapeutic effects of a drug whereas 
the other enantiomer is inactive and/or contributes to undesirable effects. In such 
a case, use of the single enantiomer would provide a superior medication and may 
be preferred over the racemic form of the drug. Single-enantiomer formulations of 
(S)-albuterol, a β2-adrenergic receptor agonist for treatment of asthma, and (S)-
omeprazole, a proton pump inhibitor for treatment of gastroesophageal reflux, 
have been shown to be superior to their racemic formulations in clinical trials.”11   
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Because AChE is chiral, the diastereomers and enantiomers for compounds 2.8 to 2.11 
will have different resurrection reactivities. Therefore, the goal of my purification technique 
was to separate out the diastereomers to see their individual effects on reactivation of the 
inhibited AChE. The first attempt to separate the diastereomers included using column 
chromatography. This technique failed to separate out the two compounds. The next 
attempt to separate the diastereomers was preparative TLC, which is useful at separating 
compounds that are close in polarity. This method also failed. The last attempt was high 
performance liquid chromatography or HPLC.  
Using the HPLC techniques, the diastereomers were able to be separated and 
large enough quantities to be screened. For complete characterization, 1HNMR, 13 C 
NMR, HPLC and mass spectrometry was taken to verify the target compound was 
















Experimental Details  
 
2.3: (S)-2-((2-(hydroxymethyl)pyrrolidine-1yl)methyl)pyridin-3-ol. (S)-Pyrrolidin-2-
ylmethanol (0.0205 mL, 2085 mmol, 2.0 equiv.), acetonitrile (15 mL), 2-bromomethyl-3-
hrdroxypyridine hydrobromide (0.280 g, 1.043 mmol, 1.0 equiv.), potassium carbonate 
(0.288 g, 2.085 mmol, 2.0 equiv.) combined in a round bottom flask and refluxed at 100 
°C for 3 h. Distilled water (20 mL) was added to the solution and then was extracted with 
dichloromethane (4 x 10 mL). The organic layers were collected and dried with anhydrous 
sodium sulfate, and the solvent was evaporated off under reduced pressure at 35 ⁰C. The 
crude product was purified using a column with a gradient of 











2.4: 2-((1H-pyrrol-1-yl)methyl)pyridin-3-ol. Pyrrole (0.03095 mL, 0.44616 mmol, 1.2 
equiv.), acetonitrile (5 mL), 2-bromomethyl-3-hrdroxypyridine hydrobromide (0.100 g, 
0.3718 mmol, 1.0 equiv.), potassium hydroxide (0.04589 g, 0.81796 mmol, 2.2 equiv.) 
combined in a round bottom flask and refluxed at 80 °C for 3 h. Distilled water (10 mL) 
was added to the solution and then was extracted with diethyl ether (3 x 10 mL). The 
organic layers were collected and dried with anhydrous sodium sulfate, and the solvent 
was evaporated off under reduced pressure at 35 oC. The crude product was purified by 
column chromatography with a gradient of 20%methanol:dichloromethane to yield 2.4 
















Methylpyrrolidine (0.044 mL, 0.4375 mmol, 1.5 equiv.) was added to methanol (10 mL) 
and stirred in a 50mL round bottom flask at room temperature. Hydrochloric acid (0.0155 
mL, 0.3208 mmol, 1.72 equiv.) was added dropwise over three minutes to the solution. 
3-methoxypicolinaldehyde (0.4 g, 0.2916 mmol, 1 equiv.) was added after the 
Hydrochloric acid. The solution was refluxed and stirred at 23 °C for 12 h. Sodium 
cyanoborohydride (0.0504 g, 0.8021 mmol, 1.1 equiv) was added to the mixture after the 
12 h reflux. The solution was refluxed and stirred at 73 °C for 12h and then allowed to 
cool to room temperature. Distilled water (20 mL) was added to the solution and then was 
extracted with dichloromethane (3 x 10 mL). The organic layers were collected and dried 
with anhydrous sodium sulfate, and the solvent was evaporated off under reduced 
pressure at 35 ⁰C. The crude product was purified by column chromatography with a 








2.8a and 2.8b:2-(1-((R)-2-methylpyrrolidin-1-yl)ethyl)pyridine-3-ol. (R)-2-
Methylpyrrolidine (0.116 mL, 1.09376 mmol, 1.5 equiv.) was added to methanol (10 mL) 
and stirred in a 50 mL round bottom flask at room temperature. Hydrochloric acid (0.03879 
mL, 1.2548 mmol, 1.72 equiv.) was added dropwise over three minutes to the solution. 
1-(3-Hydroxypyridin-2-yl)ethan-1-one (1.0 g, 0.7292 mmol, 1 equiv.) was added after the 
hydrochloric acid. The solution was refluxed and stirred at 73 °C for 12 h. Sodium 
cyanoborohydride (0.0504 g, 0.8021 mmol, 1.1 equiv.) was added to the mixture after the 
12 h reflux. The solution was refluxed and stirred at 73 °C for 12h. The crude product was 
HPLC to isolate the diastereomers. The solvent was evaporated off under reduced 
pressure at 75 °C for both diastereomers to yield 2.8a (0.0673 g, 0.3249 mmol, 44.6%) 
and 2.8b (0.0398 g, 0.1921 mmol, 26.36%). Expected Mass [C12H8N2O = 206.1419], 










2.9a and 2.9b: 2-(1-((S)-2-methylpyrrolidin-1-yl)ethyl)pyridine-3-ol. (S)-2-
Methylpyrrolidine (0.116 mL, 1.09376 mmol, 1.5 equiv.) was added to methanol (10 mL) 
and stirred in a 50mL round bottom flask at room temperature. Hydrochloric acid (0.03874 
mL, 1.2542 mmol, 1.72 equiv.) was added dropwise over three minutes to the solution. 
1-(3-Hydroxypyridin-2-yl)ethan-1-one (1.0 g, 0.7292 mmol, 1 equiv.) was added after the 
hydrochloric acid. The solution was refluxed and stirred at 73 °C for 12 h. Sodium 
cyanoborohydride (0.0504 g, 0.8021 mmol, 1.1 equiv.) was added to the mixture after the 
12 h reflux. The solution was refluxed and stirred at 73 °C for 12 h. The crude product 
was HPLC to isolate the diastereomers. The solvent was evaporated off under reduced 
pressure at 75 ⁰C for both diastereomers to yield 2.9a (0.0139 g, 0.0671 mmol, 9.20%) 
and 2.9b. (0.0153 g, 0.07386 mmol, 10.13%). Expected Mass [C12H8N2O = 206.1419], 









2.10: 2-(1-(pyrrolidin-1-yl)ethyl)pyridine-3-ol. Pyrrolidine (0.0913 mL, 1.09376 
mmol,1.5 equiv.) was added to methanol (10 mL) and stirred in a 50 mL round bottom 
flask at room temperature. Hydrochloric acid (0.03879 mL, 1.2548 mmol, 1.72 equiv.) was 
added dropwise over three minutes to the solution. 1-(3-Hydroxypyridin-2-yl)ethan-1-one 
(1.0 g, 0.7292 mmol, 1 equiv.) was added after the Hydrochloric acid. The solution was 
refluxed and stirred at 73 °C for 12 h. Sodium cyanoborohydride (0.0504 g,0.8021 mmol, 
1.1 equiv.) was added to the mixture after the 12 h reflux. The solution was refluxed and 
stirred at 73 °C for 12 h. The crude product was purified by HPLC to isolate the 
diastereomers. The solvent was evaporated off under reduced pressure at 75 °C to yield 












2.11: 2-(1-(diethylamio)ethyl)pyridine-3-ol. Diethylamine (0.06006 mL, 0.80212 mmol, 
2.2 equiv.) was added to methanol (10 mL) and stirred in a 50mL round bottom flask at 
room temperature. Hydrochloric acid (0.01973 mL, 0.62709 mmol, 1.72 equiv.) was 
added dropwise over three minutes to the solution. 1-(3-h]Hydroxypyridin-2-yl)ethan-1-
one (0.5 g , 0.3546 mmol, 1 equiv.) was added after the hydrochloric acid. The solution 
was refluxed and stirred at 73 °C for 12 h. Sodium cyanoborohydride (0.0252 g, 0.4010 
mmol, 1.1 equiv.) was added to the mixture after the 12 h reflux. The solution was refluxed 
and stirred at 73 °C for 12 h. The crude product was purified by HPLC to isolate the 
diastereomers. The solvent was evaporated off under reduced pressure at 75 °C to yield 
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Chapter 3: Biological Testing and Future Work 
 
3.1 Kinetic Studies  
Once the compounds were purified and characterized, they are tested for the 
alkylator’s biological effects with the aged form of AChE. Initially, electric eel AChE was 
added with an OP. However, the positive control was native AChE that had not been 
exposed to an OP (native AChE). The negative control was the aged AChE; however, no 
QMPs, purified compounds, or 2-PAM were added. The positive and negative controls 
are important for comparing the evaluated compound’s biological effect and its 
significance in resurrecting some activity of the native AChE. The negative control is only 
aged AChE with no addition of any compound; the aged AChE activity of the negative 
control provides a baseline for the small percentage that did not fully age. The amount of 
unaged AChE is usually less than 0.5% for the negative control. This percentage is 
compared to the percentage of resurrected AChE when the newly synthesized molecules 
are added to ensure the percentage is higher than the negative’s control. If the percentage 
is close to zero or the negative control’s percentage, then the tested molecule is inactive 
and has no effect on the realkylating or resurrecting of the aged form of AChE. For testing 
the purified compounds described in Chapter 2, positive and negative control for two 
different OPs, specifcially PiMP and DFP, were used as the AChE inhibitors (Scheme 3.1 





Scheme 3.1. Aging of AChE with DFP 
 
Scheme 3.2. Aging of AChE with PiMP 
PiMP is a simulant of an authentic chemical warfare agent or nerve agent while 
DFP is a pesticide. Ellman’s assay is used to determine the activity of 
acetylcholinesterase (AChE). Ellman’s assay monitors the activity of the enzyme by 
hydrolyzing acetylthiocholine into thiocholine instead of acetylcholine to choline (Scheme 
3.3).1 Then, the thiocholine will then reduce the disulfide bonds in dithionitrobenzoate to 
thionitrobenzoate plus another by-product (Scheme 3.4).1  
 




Scheme 3.4. The reaction of dithionitrobenzoate and thiocholine in an Ellman’s assay 
Therefore, activity of the enzyme is monitored by the concentration of 
thionitrobenzoate via ultraviolet-visible spectroscopy because thionitrobenzoate absorbs 
light at 412 nm.1  Therefore, the absorbance directly correlates with more reactivated 
AChE. The alkylators and pure synthetic compound will be incubated with aged electric 
eel AChE for 2 days at 37 °C.1 The pure synthetic compound should re-alkylate the 
inhibited AChE like a pyridinium oxime.1 Based on the results of this last step, the target 
alkylator being evaluated will be modified for the next synthetic molecule and retested if 





Figure 3.1. Results from the screening 
 Although the goal is to have the highest relative reactivation, it has been proven 
by many sources that 10% reactivation of AChE is needed for human function. This 
percentage will be compared to the results shown in the screening. The results of the 
screening of the compounds presented in this thesis are shown in Figure 3.1. The positive 
control is not shown in the figure for simplification of presentation, but all values are 
relative to the positive control at 100%.  Compound 2.9 a, 2.9 b, 2.10, 2.11, 2.6 and 2.3 
showed no activity.  The activity AChE in the samples was less than or equal to the 
negative control. Compounds 2.8 a and 2.3 show activity in the screen’s assay or the bars 























Relative Activity DFP Aged Human AChE (24 h) with 4 mM QMP
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broken down and compared to the lead compounds discussed earlier in the thesis. The 
percentage displayed for the lead compounds (2.1 and 2.12) were all at the same pH of 
7.5, aged DFP and Human AChE. The same condition that the tested compounds were 
done in.  
 
Figure 3.2. Relative resurrection between compounds 2.1, 2.3, and 2.4 
As seen in Figure 3.2, compound 2.3 is very similar to the lead compound 
discussed earlier in this thesis.  The presence of the hydroxymethyl group added on the 
pyrrolidine decreases activity but it seems that the active site within the enzyme tolerates 
the presence of that group, but with decreased selectivity.  The low activity of compounds 








Figure 3.3. Relative resurrection between compounds 2.1, 2.12, and 2.6 
Figure 3.3 shows a comparison of the relative resurrection of the lead compound 
to 2.6. The major difference between 2.6 compared to 2.1 and 2.12 is the ester group 
instead of the hydroxyl group on the ring. The low activity of compound 2.6 demonstrates 
the presence of the phenolic group play an important role in the resurrection ability of our 
compounds.   
 
Figure 3.4. Relative resurrection between 2.1, 2.10 and 2.11 
Figure 3.4 shows a comparison of the relative activator of the lead compound 2.1 
to 2.10 and 2.11. The low activity of compound 2.10 demonstrates that adding a methyl 
group at the benzylic carbon as a negative effect the resurrection of the aged AChE. 
Similarly, the low activity of compound 2.11 shows the addition of methyl group 
regardless of amine reduced resurrection of the aged AChE was observed. However, as 
stated above, 2.10 and 2.11 are racemic. The different enantiomers can play different 
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roles in the active site. Therefore, the low activity could be due to one enantiomer being 
an inhibitor to the enzyme.  
 
Figure 3.5. Relative resurrection between 2.1, 2.9 a and 2.9 b 
Figure 3.5 shows a comparison of the relative resurrection for 2.1, 2.9 a, and 2.9 
b. The low activity of 2.9 a and 2.9 b indicate the addition of the methyl group at the 
benzylic carbon and (S)-methylpyrrolidine had a negative effect on the resurrection of 
the aged AChE.  
 
Figure 3.6. Relative resurrection between 2.1, 2.12, 2.8a, and 2.8b 
Figure 3.6 shows a comparison of both the compound’s structures and relative 
resurrection for 2.1, 2.12, 2.9 a, and 2.9 b. The most interesting values are the data for 
the diastereomeric set 2.8 a and 2.8 b.  This set of diastereomers were not able to be 
completely separated when HPLC isolation was attempted.  Therefore, the screening 
results presented above show the activity as a mixture of two diastereomers for entry 2.8 
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a and 2.8 b.  For entry 2.8 a the less polar isomer is in excess by 10% and for entry 2.8 
b the more polar isomer by HPLC is in excess by ~11%.  It is remarkable that with only a 
slight excess in one of the diastereomers, the sample screened for 2.8 a showed a 4.7% 
resurrection while when the other diastereomers is in excess in 2.8 b, the sample shows 
no activity.  This could indicate that one of the diastereomers is a potent resurrector while 
the other compound is a potent inhibitor of the enzyme.  Compound 2.9a and 2.9b did not 
show any activity indicating the stereochemistry of the 2-methylpyrrolidine needs to be 
the R configuration for activity. This result does not only prove chirality is significant in 
resurrection but also the addition of a substituent to the benzylic carbon also plays a key 
role. The addition of the methyl group to the benzylic carbon may also play a key role in 
resurrection because this compound may have more favorable conditions to form the QM 
resulting in this high relative activity. Our immediate task at hand is to resynthesize these 
frameworks and to improve the separation by HPLC so that we can confirm this idea and 
further probe the resurrection capabilities of this framework when in their pure form.   
 Due to the advancements in chemical warfare agents more specifically the toxic 
OPs that have devasting effects on individuals leading a demand for find counter 
measures. Although there are drugs that reactivate inhibited AChE, these current 
treatments have limitations. The drugs are positively charged; therefore, they can not 
pass the blood brain barrier can lead to a build up ACh in the brain causing fatal effects. 
In addition, if the drugs are not dosed correctly or administered in the correct time frame 
the inhibited AChE will become irreversibly dealkylated or aged. There are currently no 
known treatments that for re-alkylation of the aged AChE to then administer the current 
drugs to reactivate the aged AChE or resurrects the aged AChE. (Figure 3.7) The goal of 
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my research is to synthesize a small organic molecule that will resurrect the aged AChE. 
Based on my results, Compound 2.8 a showed promising results to further research and 
optimize its resurrection capabilities. 
 











3.2 Future work 
Based on the results from the kinetic study shown above, the molecules can be 
adapted to further increase its reactivity results. The diastereomers from the (R)-2-
methylpyrrolidine showed the highest reactivity. Using this framework as the goal, we plan 
to add other substituents to the pyridine ring to see the effects on the compounds rate of 
forming the QMP or its percent reactivation (Scheme 3.5).  
 
Scheme 3.5. Ethanone reduction with the addition of EDG or EWG 
 
The added substituent, X, can either be an electron donating group or electron 
withdrawing group. Based on the characteristic of an electron donating group, it is 
hypothesized that the electron donating group would increase the rate of formation of the 
QMP compared to the electron with drawing group (Scheme 3.6). This is because the 
electron donating group stabilizes the carbocation that forms making the QMP formation 
more favorable. In comparison, the electron withdrawing group destabilizes the 
carbocation making the QMP less likely to form.   
 
Scheme 3.6. QMP equilibrium 
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In addition to adding either an electron withdrawing or electron donating group, 
another question is adding another methyl group to the benzylic carbon (Scheme 3.7). 
The addition of another methyl group previously has been synthesized; however, the 
targets compound is very unstable and degrades spontaneously in water, relative to the 
QMP that has only one methyl group at this position. This is because the carbocation 
formed is a tertiary center with more substituents to stabilize the charge compared to the 
secondary carbon with one methyl group at the benzylic center. Therefore, the goal is to 
combine the addition of the methyl group at the benzylic carbon and an EWG to the 
pyridine ring to try and stabilize the target compound (Scheme 3.8). The EWG should 
make the benzylic carbon less favorable to form the carbocation since it will withdraw 
electrons from the tertiary center.  
 
Scheme 3.7. Ethanone reduction with the addition of EDG or EWG and methyl group  
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